Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

A Clinical Study of Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Chronic Stroke

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02065778

Enrollment

Registered

2014-02-19

Start date

2008-12-31

Completion date

2014-01-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Accident

Brief summary

The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.

Interventions

BIOLOGICALAutologous bone marrow mononuclear cell transplantation

bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* males and females * above 18 years of age * diagnosed as stroke by clinical and MRI findings

Exclusion criteria

* presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever * hemoglobin less than 8 * bleeding tendency * bone marrow disorder * left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Functional Independence Measure	6 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026